Beam Therapeutics (BEAM) reported a Q3 net loss Tuesday of $1.17 per share, narrowing from a loss of $1.22 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.15.
License and collaboration revenue for the quarter ended Sept. 30 was $14.3 million, down from $17.2 million a year earlier.
Analysts surveyed by Capital IQ expected $14.1 million.
The company said it had $925.8 million in cash, cash equivalents and marketable securities as of Sept. 30 to fund its operations into 2027.
Shares of the company were down over 10% in recent premarket activity.
Price: 21.60, Change: -2.76, Percent Change: -11.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。